A Competitive Analysis of the Global Asthma and COPD Therapeutics Market

Novel Inhaler Devices and Formulations are Impetuses for Growth

Regular Price: USD 3,950

Special Price USD 3,555

10% OFF

* Required Fields

Regular Price: USD 3,950

Special Price USD 3,555

PAY BY INVOICE

Be the first to review this product

The research service assesses marketed and investigational products, as well as combination regimens, for asthma and chronic obstructive pulmonary disease (COPD). Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into bronchodilators, anti-inflammatories, and combination therapies of current global interest. Novel inhaler devices, formulations, and anti-inflammatories are key drivers for the market.

Table of Contents

Executive SummaryKey FindingsKey Findings—AsthmaKey Findings—COPDOverview of Product Launches and Pipeline DevelopmentKey Companies to WatchCEO’s PerspectiveMethodology and ScopeMethodology and ScopeMarket OverviewMarket Overview—SegmentationMarket Overview—DefinitionsPrevalence of Asthma by Country/RegionPrevalence of COPD by Country/RegionAsthma and COPD Competitive LandscapeAsthma Therapeutics Market—Marketed and Pipeline ProductsAsthma Therapeutics Market—Marketed and Pipeline Products (continued)Asthma Therapeutics Market—Key Marketed Product SynopsisAsthma Therapeutics Market—Key Marketed Product Synopsis (continued)Asthma Therapeutics Market—Key Pipeline Product SynopsisAsthma Therapeutics Market—Key Pipeline Product Synopsis (continued)COPD Therapeutics Market—Marketed and Pipeline ProductsCOPD Therapeutics Market—Marketed and Pipeline Products (continued)COPD Therapeutics Market—Key Marketed Product Synopsis COPD Therapeutics Market—Key Marketed Product Synopsis (continued) COPD Therapeutics Market—Key Pipeline Product SynopsisCOPD Therapeutics Market—Key Pipeline Product Synopsis (continued)Event TimelinesTotal Asthma and COPD Therapeutics Market—Projected Launch Timeline for Key Pipeline DrugsPivotal Phase 3 TrialsEstimated Product Launch Timeline—Striverdi Respimat for Asthma and COPD by Boehringer IngelheimEstimated Product Launch Timeline—Quilizumab for Asthma by GenentechEstimated Product Launch Timeline—DuoResp Spiromax for Asthma and COPD by Teva PharmaceuticalsEstimated Product Launch Timeline—Incruse Ellipta (umeclidinium) for COPD by GSKEstimated Product Launch Timeline—Benralizumab for Asthma by AstraZenecaPatent Expiration TimelineProduct Dashboards—Marketed, Approved, and Phase 3 ProductsSeebri Breezhaler by NovartisAdvair/Seretide by GSKXolair by Genentech and NovartisAsmanex Twisthaler by Merck & Co.Spiriva by Boehringer IngelheimAirFlu Sal/Forspiro by Sandoz (Novartis)Incruse Ellipta by GSKBenralizumab by AstraZeneca Bosatria by GSKPT003 by Pearl Therapeutics (AstraZeneca)ConclusionsConclusionsLegal DisclaimerAppendixDecision Support Database—Global Prevalence of SmokersDecision Support Database—Global Prevalence of Smokers (continued)Decision Support Database—Population with COPDDecision Support Database—Population with COPD (continued)The Frost & Sullivan StoryThe Frost & Sullivan StoryValue Proposition: Future of Your Company & CareerGlobal PerspectiveIndustry Convergence360º Research PerspectiveImplementation ExcellenceOur Blue Ocean Strategy




Keyword1

Keyword2

Keyword3

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.